Inactive Instrument

Analyst Reco. ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	Dec. 04	MT
Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	Dec. 01	MT
Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	Dec. 01	MT
BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	Dec. 01	MT
Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	Dec. 01	MT
Jefferies Downgrades ImmunoGen to Hold From Buy, Raises Price Target to $31 From $25	Nov. 30	MT
William Blair Downgrades ImmunoGen to Market Perform From Outperform	Nov. 30	MT
Truist Securities Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $24	Nov. 30	MT
Canaccord Genuity Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31.26 From $25	Nov. 30	MT
HC Wainwright Downgrades ImmunoGen to Neutral From Buy, Raises Price Target to $31.26 From $28	Nov. 30	MT
Goldman Sachs Initiates ImmunoGen With Neutral Rating, $17 Price Target	Nov. 20	MT
Deutsche Bank Initiates Coverage on ImmunoGen With Buy Rating, $25 Price Target	Nov. 09	MT
Oppenheimer Initiates Coverage on ImmunoGen With Market Perform Rating, $16 Price Target	23-10-06	MT
JPMorgan Upgrades ImmunoGen to Overweight From Neutral, Adjusts Price Target to $22 From $9	23-09-13	MT
HC Wainwright Adjusts ImmunoGen's Price Target to $27 From $26, Keeps Buy Rating	23-08-29	MT
Barclays Raises Price Target on ImmunoGen to $27 From $20, Maintains Overweight Rating	23-08-02	MT
BMO Capital Adjusts Price Target on ImmunoGen to $26 From $25, Maintains Outperform Rating	23-08-01	MT
HC Wainwright Adjusts Price Target on ImmunoGen to $26 From $21, Maintains Buy Rating	23-08-01	MT
ANALYST RECOMMENDATIONS : Meta, Thermo Fisher, Union Pacific, Domino's Pizza...	23-08-01
HC Wainwright Adjusts ImmunoGen's Price Target to $21 From $15, Maintains Buy Rating	23-06-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Analyst Reco.

Filters